Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Tetratherix Limited ( (AU:TTX) ).
Tetratherix Limited has announced positive results from the initial phase of its TUTELA clinical trial, where the Tutelix hydrogel spacer was successfully implanted in patients at Gold Coast University Hospital without any adverse events. The spacer maintained its structure during radiotherapy, reducing radiation exposure to the rectum and minimizing side effects. Stage 2 of the trial has commenced, with patient recruitment underway across multiple sites in Australia, and plans for pivotal trials in Australia and the US are set to begin in 2026.
The most recent analyst rating on (AU:TTX) stock is a Buy with a A$5.76 price target. To see the full list of analyst forecasts on Tetratherix Limited stock, see the AU:TTX Stock Forecast page.
More about Tetratherix Limited
Tetratherix Limited operates in the medical technology industry, focusing on innovative solutions for healthcare. The company, in partnership with Tutelix Pty Ltd, is engaged in developing hydrogel spacer products designed to improve the safety and efficacy of radiotherapy treatments.
Average Trading Volume: 21,203
See more insights into TTX stock on TipRanks’ Stock Analysis page.